How we can reduce the burden of disease
In the long run, Credence Tumor Hotspots seeks to reduce the burden of disease by targeting prevention and treatment more effectively. With the help of tailored medical treatment, the health care management paradigm will focus on prevention, moving from illness to wellness, and from treating disease to maintaining health. At the same time, it will reduce healthcare costs by improving the physicians’ ability to quickly and reliably select effective therapy for a given patient while minimizing costs associated with ineffective treatment and avoidable adverse effects.
Personalized medicine makes use of molecular profiling techniques (genetic tests etc.) and a specific set of biomarkers (molecules that helps in tagging a biological process for better understanding and clear observation) to understand the genetic make-up of individuals.
Credence Tumor Hotspots panel
Credence Tumor Hotspots panel simultaneously screens 50 genes that are responsible for inherited predisposition to Tumor hotspots. The genes covered in the panel include;
ABL1, EZH2, JAK3, PTEN, AKT1, FBXW7, IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC, FGFR2, KIT, RET, ATM, FGFR3, KRAS, SMAD4, BRAF, FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, SMO, CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ, NOTCH1, STK11, CTNNB1, HNF1A, NPM1, TP53, EGFR, HRAS, NRAS, VHL, ERBB2, IDH1, PDGFRA, ERBB4, JAK2 and PIK3CA
- Get the benefit of the most effective personalised medication with least side effects
- Fastest possible recovery time
- Understand all available prevention methodologies
- Minimise the trauma of cancer
- Benefit from early diagnosis and reduced medical costs
Did you know?
Medical diagnosis and treatment is now drifting away from trial and error based standard medicine (where all patients with similar category of symptoms are prescribed with a single drug – one size fits all approach) to more efficacious, cost effective, personalized treatments with no side effects.